{
    "clinical_study": {
        "@rank": "72082", 
        "acronym": "FASAN", 
        "arm_group": [
            {
                "arm_group_label": "placebo ,anorexia nervosa", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2x3 placebo capsules with olive oil"
            }, 
            {
                "arm_group_label": "fatty acids preparation- eye-q", 
                "arm_group_type": "Experimental", 
                "description": "2 x 3  tablets of eye -q preparation daily ( 558 mg  of EPA, 175 mg  of DHA, 60 mg fo GLA)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether omega -3 fatty acids are effective and\n      safe in treating anorexia nervosa."
        }, 
        "brief_title": "Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Anorexia Nervosa", 
        "condition_browse": {
            "mesh_term": [
                "Anorexia", 
                "Anorexia Nervosa"
            ]
        }, 
        "detailed_description": {
            "textblock": "10-week, randomized, placebo-controlled, parallel-group study to compare the efficacy and\n      safety of omega-3 fatty acids with placebo in the treatment of anorexia nervosa. Patients\n      will be randomly assigned to blinded study treatment. Double-blind treatment will be\n      preceded by a medication washout period of 1-28 days if necessary. Some patients may be\n      taking anti-depressants or anti-psychotics, e.g. fluoxetine, prior to admission to the\n      study. In such case the wash out period will depend on the medical treatment (dependent on\n      the drug given) given prior to qualification to the study. Patient will be treated as\n      inpatients during 10 weeks of the study. The study will recruit female inpatients with\n      anorexia nervosa (aged 12 to 19 years), with DSM-IV and ICD-10 diagnosis of anorexia\n      nervosa.BMI below 5 percentile and EAT-26 score > 30 is required at both screening and\n      randomization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Anorexia nervosa (DSM IV,ICD-10)\n\n          -  Female\n\n          -  Age 12-19\n\n          -  Written informed  consent given by patient and his parents\n\n        Exclusion Criteria:\n\n          -  Lack of informed consent"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "19 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01761942", 
            "org_study_id": "22/2011", 
            "secondary_id": "22/2011"
        }, 
        "intervention": {
            "arm_group_label": "fatty acids preparation- eye-q", 
            "description": "3x2 tablets daily by 70 days", 
            "intervention_name": "fatty acids preparation- eye-q", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "omega-3 fatty acids", 
            "anorexia nervosa", 
            "efficacy", 
            "safety"
        ], 
        "lastchanged_date": "January 3, 2013", 
        "location": {
            "contact": {
                "email": "askapb@wp.pl", 
                "last_name": "Agnieszka Pir\u00f3g-Balcerzak, MD", 
                "phone": "48-606-43-15-74"
            }, 
            "facility": {
                "address": {
                    "city": "Warsaw", 
                    "country": "Poland", 
                    "state": "Mazowieckie", 
                    "zip": "02-957"
                }, 
                "name": "Institute of Psychiatry and Neurology,"
            }, 
            "investigator": {
                "last_name": "Agnieszka Pir\u00f3g-Balcerzak, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 10-week Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Omega-3 Fatty Acids Oral Capsules Compared With Placebo in the Treatment of Anorexia Nervosa", 
        "overall_contact": {
            "email": "askapb@wp.pl", 
            "last_name": "Agnieszka Pir\u00f3g-Balcerzak, MD", 
            "phone": "48606431574"
        }, 
        "overall_official": {
            "affiliation": "Institute of Psychiatry and Neurology, Warsaw", 
            "last_name": "Agnieszka Pir\u00f3g-Balcerzak, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Poland: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to compare the efficacy of EPA fatty acids with that of placebo as add-on treatment for inpatients with anorexia nervosa, as assessed by the change from baseline to day 70 in BMI (body mass index)", 
            "measure": "Omega-3 fatty acids are superior to placebo in increasing BMI at day 70 compared with baseline", 
            "safety_issue": "No", 
            "time_frame": "day 70th"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01761942"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Institute of Psychiatry and Neurology, Warsaw", 
            "investigator_full_name": "Agnieszka Pir\u00f3g-Balcerzak", 
            "investigator_title": "MD, psychiatrist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "1.\tTo compare the effects of omega-3/6 fatty acids with the effect of placebo in reducing EAT-26 (Eating Attitude Test-26) total score at day 70 compared with baseline", 
                "measure": "reducing EAT -26", 
                "safety_issue": "No", 
                "time_frame": "day 70th"
            }, 
            {
                "description": "to compare the effects of fatty acids with the effect of placebo by \tchange from baseline to day 70 in CGI (Clinical Global Impression)", 
                "measure": "changes in CGI", 
                "safety_issue": "No", 
                "time_frame": "day 70th"
            }, 
            {
                "description": "to compare the effects of fatty acids with the effect of placebo on change form baseline to day 70 in Hamilton Depression Rating Scale", 
                "measure": "change in HDRS", 
                "safety_issue": "No", 
                "time_frame": "day 70 th"
            }, 
            {
                "description": "to compare the effects of fatty acids with the effect of placebo by change form baseline to day 70   in Beck Depression Inventory", 
                "measure": "changes in BDI", 
                "safety_issue": "No", 
                "time_frame": "day 70th"
            }, 
            {
                "description": "to compare the effects of fatty acids with the effect of placebo by changes in  Yale-Brown Obsessive-Compulsive Scale", 
                "measure": "changes in YBOCS", 
                "safety_issue": "No", 
                "time_frame": "day 70 th"
            }, 
            {
                "description": "to compare the effects of fatty acids with the effect of placebo by \tchange form baseline to day 70   Yale-Brown Obsessive-Compulsive Scale", 
                "measure": "changes in YBOCS", 
                "safety_issue": "No", 
                "time_frame": "day 70th"
            }, 
            {
                "description": "to evaluate the safety and tolerability of omega-3 fatty acids compared with placebo in the treatment of anorexia nervosa, as assessed by \tincidence and nature of adverse events", 
                "measure": "adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "70 days time"
            }, 
            {
                "description": "to evaluate the safety and tolerability of omega-3 fatty acids compared with placebo in the treatment of anorexia nervosa, as assessed by changes from baseline to day 70 in clinical laboratory tests (lipids metabolism - triglycerides, HDL and LDL cholesterol)", 
                "measure": "clinical laboratory tests", 
                "safety_issue": "No", 
                "time_frame": "day 70 th"
            }
        ], 
        "source": "Institute of Psychiatry and Neurology, Warsaw", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute of Psychiatry and Neurology, Warsaw", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}